Literature DB >> 31892915

Comparative Effectiveness Research in Inflammatory Bowel Disease: The VARSITY Study and Beyond.

Bruce E Sands1.   

Abstract

Year:  2019        PMID： 31892915      PMCID： PMC6935026     

Source DB:  PubMed          Journal:  Gastroenterol Hepatol (N Y)        ISSN： 1554-7914


× No keyword cloud information.
  4 in total

1.  Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis.

Authors:  Bruce E Sands; Laurent Peyrin-Biroulet; Edward V Loftus; Silvio Danese; Jean-Frédéric Colombel; Murat Törüner; Laimas Jonaitis; Brihad Abhyankar; Jingjing Chen; Raquel Rogers; Richard A Lirio; Jeffrey D Bornstein; Stefan Schreiber
Journal:  N Engl J Med       Date:  2019-09-26       Impact factor: 91.245

2.  What is the need for comparative effectiveness studies in IBD?

Authors:  Mark H Flasar; Raymond K Cross
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2014-08-06       Impact factor: 3.869

Review 3.  Effectiveness Research in Inflammatory Bowel Disease: A Necessity and a Methodological Challenge.

Authors:  Julia Salleron; Silvio Danese; Laurence D'Agay; Laurent Peyrin-Biroulet
Journal:  J Crohns Colitis       Date:  2016-03-03       Impact factor: 9.071

4.  Setting priorities for comparative effectiveness research in inflammatory bowel disease: results of an international provider survey, expert RAND panel, and patient focus groups.

Authors:  A S Cheifetz; G Y Melmed; B Spiegel; J Talley; S M Devlin; L Raffals; P M Irving; J Jones; G G Kaplan; P Kozuch; M Sparrow; F Velayos; L Baidoo; B Bressler; C A Siegel
Journal:  Inflamm Bowel Dis       Date:  2012-02-15       Impact factor: 5.325
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.